대장암 진단 시장 : 전략적 인사이트와 예측(2026-2035년)

The Colorectal Cancer Diagnostics Market is anticipated to grow at a CAGR of 9.3% from USD 8.91 billion in 2026 to USD 19.81 billion in 2035.

Colorectal cancer diagnostics have become an essential component of modern oncology as early detection significantly improves patient survival and treatment outcomes. Healthcare systems worldwide are strengthening cancer screening initiatives to identify colorectal cancer at earlier stages while reducing disease-related mortality. The market encompasses screening, disease confirmation, molecular profiling, companion diagnostics, recurrence monitoring, and treatment selection. Growing awareness of colorectal cancer prevention, favorable screening guidelines, and advancements in artificial intelligence, liquid biopsy, and genomic diagnostics continue to transform clinical practice. Diagnostic manufacturers are increasingly investing in innovative technologies that deliver greater accuracy, faster turnaround times, and improved patient compliance.

Market Drivers

Expansion of Population Screening Programs

Governments and healthcare organizations continue expanding colorectal cancer screening initiatives as early detection remains the most effective strategy for reducing mortality. Growing adoption of fecal immunochemical tests (FIT), stool DNA tests, and colonoscopy-based screening is increasing diagnostic volumes globally.

Growing Adoption of Precision Oncology

Precision medicine is increasing the need for molecular and genomic biomarker testing to support treatment selection, companion diagnostics, and personalized therapeutic decisions. As targeted therapies become more common, demand for advanced diagnostic platforms continues to rise.

Shift Toward Minimally Invasive Testing

Healthcare providers are increasingly adopting stool-based molecular testing, liquid biopsy, and blood-based screening technologies to improve patient participation while reducing reliance on invasive diagnostic procedures. These technologies are expected to complement traditional colonoscopy rather than replace it.

Artificial Intelligence Integration

Artificial intelligence is improving image interpretation, pathology workflows, diagnostic accuracy, and laboratory efficiency. AI-assisted diagnostic platforms are supporting earlier detection while reducing diagnostic variability across healthcare settings.

Market Restraints

High Cost of Advanced Molecular Diagnostics

Genomic testing, liquid biopsy, and next-generation sequencing remain relatively expensive, limiting widespread adoption in cost-sensitive healthcare systems.

Limited Access in Developing Regions

Many emerging markets continue facing shortages of diagnostic laboratories, trained specialists, and screening infrastructure, restricting access to timely colorectal cancer diagnosis.

Regulatory and Validation Requirements

Manufacturers must conduct extensive analytical and clinical validation studies before new diagnostic technologies receive regulatory approval and broad clinical adoption.

Market and Technology Insights

The global colorectal cancer diagnostics market can be segmented by product & service, diagnostic technology, application, end user, and geography.

By product & service, the market includes instruments, reagents & consumables, software & diagnostic analytics solutions, and diagnostic testing services. Reagents and consumables continue to account for a substantial share because of recurring laboratory testing demand.

By diagnostic technology, the market comprises fecal immunochemical tests (FIT), guaiac fecal occult blood tests (gFOBT), stool DNA testing, colonoscopy-based diagnostics, flexible sigmoidoscopy, CT colonography, molecular and genomic testing, and liquid biopsy testing. Molecular diagnostics and liquid biopsy technologies are expected to experience rapid growth as precision oncology expands.

By application, diagnostics support screening and early detection, diagnosis and disease confirmation, prognostic assessment, treatment selection and companion diagnostics, and recurrence monitoring. Screening remains the largest application owing to increasing preventive healthcare initiatives worldwide.

By end user, the market includes hospitals, diagnostic laboratories, cancer centers, academic & research institutes, and other healthcare facilities. Diagnostic laboratories continue expanding molecular testing capacity to accommodate increasing screening volumes.

Market Trends

The colorectal cancer diagnostics market continues evolving through technological innovation.

Key trends include:

• Expansion of stool-based screening programs.
• Rapid development of liquid biopsy technologies.
• Increasing use of molecular and genomic biomarkers.
• Artificial intelligence integration into pathology and imaging.
• Growing adoption of companion diagnostics.
• Expansion of multi-cancer early detection technologies.
• Greater laboratory automation and digital workflow integration.

Regional Insights

North America remains the largest colorectal cancer diagnostics market because of extensive screening programs, advanced healthcare infrastructure, favorable reimbursement, and widespread adoption of precision oncology technologies.

Europe continues to maintain a significant market share through organized national screening initiatives, standardized clinical guidelines, and increasing molecular diagnostic adoption.

Asia-Pacific is expected to register the fastest growth owing to increasing cancer incidence, improving healthcare infrastructure, expanding diagnostic capacity, and rising government investment in preventive oncology. China, Japan, India, South Korea, and Australia are major contributors to regional growth.

Latin America and the Middle East & Africa are gradually expanding colorectal cancer screening through healthcare modernization and improved diagnostic accessibility.

Competitive Landscape

The market consists of global diagnostics manufacturers, molecular diagnostics companies, laboratory service providers, and biotechnology firms. Companies continue investing in molecular diagnostics, liquid biopsy platforms, companion diagnostics, artificial intelligence, and digital pathology solutions to strengthen their competitive positions. Strategic collaborations, acquisitions, and product launches remain central to market expansion.

Major companies include Exact Sciences Corporation, Guardant Health Inc., F. Hoffmann-La Roche Ltd., QIAGEN N.V., Abbott Laboratories, Thermo Fisher Scientific Inc., Danaher Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Epigenomics AG, Freenome Holdings Inc., Geneoscopy Inc., Novigenix SA, Mainz Biomed N.V., and Eiken Chemical Co., Ltd.

Future Outlook

The future of the colorectal cancer diagnostics market will increasingly focus on earlier, less invasive detection supported by molecular diagnostics, liquid biopsy, artificial intelligence, and multi-omics technologies. Growing integration of precision oncology into routine clinical practice will continue increasing demand for genomic characterization and companion diagnostics. Continued investment in blood-based screening technologies and digital diagnostic workflows is expected to improve patient participation while enhancing diagnostic accuracy and healthcare efficiency.

Conclusion

The Global Colorectal Cancer Diagnostics Market is expected to experience strong growth through 2035, supported by expanding screening initiatives, increasing precision medicine adoption, and rapid technological innovation. Although cost, regulatory requirements, and healthcare infrastructure disparities remain important challenges, advances in molecular diagnostics, liquid biopsy, artificial intelligence, and personalized oncology are expected to create substantial opportunities for diagnostic manufacturers, healthcare providers, laboratories, researchers, and investors.

Key Benefits of this Report

• Comprehensive assessment of the global colorectal cancer diagnostics market.
• Detailed evaluation of diagnostic technologies, molecular innovations, and market trends.
• Analysis of competitive strategies, regulatory developments, and commercialization opportunities.
• Insights into precision oncology, liquid biopsy, and AI-driven diagnostic advancements.
• Valuable resource for diagnostic manufacturers, biotechnology companies, laboratories, healthcare providers, researchers, investors, and policymakers.

What Businesses Use Our Reports For

Market opportunity assessment, product portfolio planning, competitive benchmarking, commercialization strategy, investment analysis, partnership evaluation, regulatory planning, laboratory expansion, and long-term strategic decision-making.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global colorectal cancer diagnostics market by product & service, diagnostic technology, application, end user, and geography
• Evaluation of market dynamics, technological innovations, competitive landscape, regulatory environment, and future growth opportunities
• Assessment of molecular diagnostics, liquid biopsy, precision oncology, AI integration, digital pathology, companion diagnostics, and commercialization strategies
• Analysis of FIT, gFOBT, stool DNA testing, colonoscopy-based diagnostics, flexible sigmoidoscopy, CT colonography, molecular and genomic testing, liquid biopsy testing, diagnostic services, and emerging colorectal cancer diagnostic technologies through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Colorectal Cancer Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Disease Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast Analysis (2026-2035)
• 3.7 Disease Burden and Unmet Diagnostic Needs
• 3.8 Epidemiology and Prevalence Analysis
• 3.9 Diagnosed Patient Population Analysis
• 3.10 Screening and Testing Volume Analysis
• 3.11 Patient Journey Analysis
• 3.12 Colorectal Cancer Screening Landscape
• 3.13 Precision Oncology Diagnostics Overview

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies in Colorectal Cancer Diagnostics
• 6.2 Product Innovation Analysis
• 6.3 Liquid Biopsy Advancements
• 6.4 Molecular and Genomic Biomarker Developments
• 6.5 Multi-Cancer Early Detection Technologies
• 6.6 Clinical Trial Analysis
• 6.7 Pipeline Analysis
• 6.8 AI Integration in Colorectal Cancer Detection
• 6.9 Digital Pathology and Diagnostic Workflow Integration
• 6.10 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Colorectal Cancer Diagnostics Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Biomarker Type
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Testing Methodology
• 8.6 Analysis by Screening versus Diagnostic Testing
• 8.7 Analysis by End User

9. Colorectal Cancer Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Product & Service
  • 9.1.1 Instruments
  • 9.1.2 Reagents & Consumables
  • 9.1.3 Software & Diagnostic Analytics Solutions
  • 9.1.4 Diagnostic Testing Services
• 9.2 By Diagnostic Technology
  • 9.2.1 Fecal Immunochemical Test (FIT)
  • 9.2.2 Guaiac Fecal Occult Blood Test (gFOBT)
  • 9.2.3 Stool DNA Testing
  • 9.2.4 Colonoscopy-Based Diagnostics
  • 9.2.5 Flexible Sigmoidoscopy
  • 9.2.6 CT Colonography
  • 9.2.7 Molecular and Genomic Testing
  • 9.2.8 Liquid Biopsy Testing
• 9.3 By Application
  • 9.3.1 Screening and Early Detection
  • 9.3.2 Diagnosis and Disease Confirmation
  • 9.3.3 Prognostic Assessment
  • 9.3.4 Treatment Selection and Companion Diagnostics
  • 9.3.5 Recurrence Monitoring
• 9.4 By End User
  • 9.4.1 Hospitals
  • 9.4.2 Diagnostic Laboratories
  • 9.4.3 Cancer Centers
  • 9.4.4 Academic & Research Institutes
  • 9.4.5 Other End Users

10. Colorectal Cancer Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Colorectal Cancer Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 China
• 11.10 Japan
• 11.11 South Korea
• 11.12 Australia
• 11.13 India
• 11.14 Brazil
• 11.15 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 Exact Sciences Corporation
• 13.2 Guardant Health, Inc.
• 13.3 F. Hoffmann-La Roche Ltd
• 13.4 QIAGEN N.V.
• 13.5 Abbott Laboratories
• 13.6 Thermo Fisher Scientific Inc.
• 13.7 Danaher Corporation
• 13.8 Bio-Rad Laboratories, Inc.
• 13.9 Sysmex Corporation
• 13.10 Epigenomics AG
• 13.11 Freenome Holdings, Inc.
• 13.12 Geneoscopy, Inc.
• 13.13 Novigenix SA
• 13.14 Mainz Biomed N.V.
• 13.15 Eiken Chemical Co., Ltd.

14. Colorectal Cancer Diagnostics Market Commercial Forecast Analysis

• 14.1 Forecast by Instruments
• 14.2 Forecast by Reagents & Consumables
• 14.3 Forecast by Software & Diagnostic Analytics Solutions
• 14.4 Forecast by Diagnostic Testing Services
• 14.5 Forecast by Stool-Based Testing
• 14.6 Forecast by Colonoscopy-Based Diagnostics
• 14.7 Forecast by Molecular and Genomic Testing
• 14.8 Forecast by Liquid Biopsy Testing

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends